<DOC>
	<DOC>NCT00136955</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer</brief_summary>
	<brief_title>Irinotecan Study For Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically documented, advanced or recurrent squamous cell carcinoma of uterine cervix. Patients may have received concurrent (with radiotherapy) or (neo)adjuvant (before or after local treatment) chemotherapy for primary tumor providing that at least 6 months have passed from the completion of previous therapy and the diagnosis of recurrent disease was documented Having measurable lesion(s), without previous radiation therapy. Patients had ever received primary chemotherapy for cervical cancer other than mentioned previously (in the inclusion criteria). Patients ever received cisplatin with total dose &gt; 300 mg/m2 and received radiotherapy or local treatment delivered to the target lesion.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Weekly Irinotecan(60mg/sqm, D1, 8, 15) in combination with Cisplatin (60mg/sqm, D1), Squamous Cell Carcinoma Of The Uterine Cervix</keyword>
</DOC>